Individualized versus standard diet fortification for growth and development in preterm infants receiving human milk

Veronica Fabrizio, Jennifer M Trzaski, Elizabeth A Brownell, Patricia Esposito, Shabnam Lainwala, Mary M Lussier, James I Hagadorn, Veronica Fabrizio, Jennifer M Trzaski, Elizabeth A Brownell, Patricia Esposito, Shabnam Lainwala, Mary M Lussier, James I Hagadorn

Abstract

Background: Human milk as compared to formula reduces morbidity in preterm infants but requires fortification to meet their nutritional needs and to reduce the risk of extrauterine growth failure. Standard fortification methods are not individualized to the infant and assume that breast milk is uniform in nutritional content. Strategies for individualizing fortification are available; however it is not known whether these are safe, or if they improve outcomes in preterm infants.

Objectives: To determine whether individualizing fortification of breast milk feeds in response to infant blood urea nitrogen (adjustable fortification) or to breast milk macronutrient content as measured with a milk analyzer (targeted fortification) reduces mortality and morbidity and promotes growth and development compared to standard, non-individualized fortification for preterm infants receiving human milk at < 37 weeks' gestation or at birth weight < 2500 grams.

Search methods: We used the standard search strategy of Cochrane Neonatal to search the Cochrane Central Register of Controlled Trials (CENTRAL; 2019, Issue 9), in the Cochrane Library; Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions(R); and the Cumulative Index to Nursing and Allied Health Literature (CINAHL), on September 20, 2019. We also searched clinical trials databases and the reference lists of retrieved articles for pertinent randomized controlled trials (RCTs) and quasi-randomized trials.

Selection criteria: We considered randomized, quasi-randomized, and cluster-randomized controlled trials of preterm infants fed exclusively breast milk that compared a standard non-individualized fortification strategy to individualized fortification using a targeted or adjustable strategy. We considered studies that examined any use of fortification in eligible infants for a minimum duration of two weeks, initiated at any time during enteral feeding, and providing any regimen of human milk feeding.

Data collection and analysis: Data were collected using the standard methods of Cochrane Neonatal. Two review authors evaluated the quality of the studies and extracted data. We reported analyses of continuous data using mean differences (MDs), and dichotomous data using risk ratios (RRs). We used the GRADE approach to assess the certainty of evidence.

Main results: Data were extracted from seven RCTs, resulting in eight publications (521 total participants were enrolled among these studies), with duration of study interventions ranging from two to seven weeks. As compared to standard non-individualized fortification, individualized (targeted or adjustable) fortification of enteral feeds probably increased weight gain during the intervention (typical mean difference [MD] 1.88 g/kg/d, 95% confidence interval [CI] 1.26 to 2.50; 6 studies, 345 participants), may have increased length gain during the intervention (typical MD 0.43 mm/d, 95% CI 0.32 to 0.53; 5 studies, 242 participants), and may have increased head circumference gain during the intervention (typical MD 0.14 mm/d, 95% CI 0.06 to 0.23; 5 studies, 242 participants). Compared to standard non-individualized fortification, targeted fortification probably increased weight gain during the intervention (typical MD 1.87 g/kg/d, 95% CI 1.15 to 2.58; 4 studies, 269 participants) and may have increased length gain during the intervention (typical MD 0.45 mm/d, 95% CI 0.32 to 0.57; 3 studies, 166 participants). Adjustable fortification probably increased weight gain during the intervention (typical MD 2.86 g/kg/d, 95% CI 1.69 to 4.03; 3 studies, 96 participants), probably increased gain in length during the intervention (typical MD 0.54 mm/d, 95% CI 0.38 to 0.7; 3 studies, 96 participants), and increased gain in head circumference during the intervention (typical MD 0.36 mm/d, 95% CI 0.21 to 0.5; 3 studies, 96 participants). We are uncertain whether there are differences between individualized versus standard fortification strategies in the incidence of in-hospital mortality, bronchopulmonary dysplasia, necrotizing enterocolitis, culture-proven late-onset bacterial sepsis, retinopathy of prematurity, osteopenia, length of hospital stay, or post-hospital discharge growth. No study reported severe neurodevelopmental disability as an outcome. One study that was published after our literature search was completed is awaiting classification.

Authors' conclusions: We found moderate- to low-certainty evidence suggesting that individualized (either targeted or adjustable) fortification of enteral feeds in very low birth weight infants increases growth velocity of weight, length, and head circumference during the intervention compared with standard non-individualized fortification. Evidence showing important in-hospital and post-discharge clinical outcomes was sparse and of very low certainty, precluding inferences regarding safety or clinical benefits beyond short-term growth.

Trial registration: ClinicalTrials.gov NCT01487928 NCT01609894.

Conflict of interest statement

VF on the Mothers' Milk Bank Northeast Advisory Board in a voluntary capacity. This is a non‐profit community milk bank that provides donated, pasteurized human milk. JMT has no interests to declare. EAB has no interests to declare. PE has no interests to declare. SL has no interests to declare. MML has no interests to declare. JIH has no interests to declare.

Core editorial and administrative support for this review has been provided by a grant from The Gerber Foundation. The Gerber Foundation is a separately endowed, private foundation, independent from the Gerber Products Company. The grantor has no input on the content of the review or the editorial process (see Sources of support).

Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Figures

1
1
Study flow diagram.
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
1.1. Analysis
1.1. Analysis
Comparison 1: Targeted or adjustable vs standard, Outcome 1: Growth velocity, weight, g/kg/d, end of intervention
1.2. Analysis
1.2. Analysis
Comparison 1: Targeted or adjustable vs standard, Outcome 2: Growth velocity, length, mm/d, end of intervention
1.3. Analysis
1.3. Analysis
Comparison 1: Targeted or adjustable vs standard, Outcome 3: Growth velocity, head circumference, mm/d, end of intervention
1.4. Analysis
1.4. Analysis
Comparison 1: Targeted or adjustable vs standard, Outcome 4: Bronchopulmonary dysplasia
1.5. Analysis
1.5. Analysis
Comparison 1: Targeted or adjustable vs standard, Outcome 5: Retinopathy of prematurity, any
1.6. Analysis
1.6. Analysis
Comparison 1: Targeted or adjustable vs standard, Outcome 6: Osteopenia
2.1. Analysis
2.1. Analysis
Comparison 2: Targeted vs standard fortification, Outcome 1: Growth velocity, weight, g/kg/d, end of intervention
2.2. Analysis
2.2. Analysis
Comparison 2: Targeted vs standard fortification, Outcome 2: Growth velocity, weight, g/kg/d, start of fortification to 40 weeks' PMA
2.3. Analysis
2.3. Analysis
Comparison 2: Targeted vs standard fortification, Outcome 3: Growth velocity, weight, g/kg/d, start of fortification to 3 months' CA
2.4. Analysis
2.4. Analysis
Comparison 2: Targeted vs standard fortification, Outcome 4: Growth velocity, weight, g/kg/d, start of fortification to 6 months' CA
2.5. Analysis
2.5. Analysis
Comparison 2: Targeted vs standard fortification, Outcome 5: Growth velocity, weight, g/kg/d, start of fortification to 12 months' CA
2.6. Analysis
2.6. Analysis
Comparison 2: Targeted vs standard fortification, Outcome 6: Growth velocity, length, mm/d, end of intervention
2.7. Analysis
2.7. Analysis
Comparison 2: Targeted vs standard fortification, Outcome 7: Growth velocity, length, mm/d, start of fortification to 40 weeks' PMA
2.8. Analysis
2.8. Analysis
Comparison 2: Targeted vs standard fortification, Outcome 8: Growth velocity, length, mm/d, start of fortification to 3 months' CA
2.9. Analysis
2.9. Analysis
Comparison 2: Targeted vs standard fortification, Outcome 9: Growth velocity, length, mm/d, start of fortification to 6 months' CA
2.10. Analysis
2.10. Analysis
Comparison 2: Targeted vs standard fortification, Outcome 10: Growth velocity, length, mm/d, start of fortification to 12 months' CA
2.11. Analysis
2.11. Analysis
Comparison 2: Targeted vs standard fortification, Outcome 11: Growth velocity, head circumference, mm/d, end of intervention
2.12. Analysis
2.12. Analysis
Comparison 2: Targeted vs standard fortification, Outcome 12: Growth velocity, head circumference, mm/d, start of fortification to 40 weeks' PMA
2.13. Analysis
2.13. Analysis
Comparison 2: Targeted vs standard fortification, Outcome 13: Growth velocity, head circumference, mm/d, start of fortification to 3 months' CA
2.14. Analysis
2.14. Analysis
Comparison 2: Targeted vs standard fortification, Outcome 14: Growth velocity, head circumference, mm/d, start of fortification to 6 months' CA
2.15. Analysis
2.15. Analysis
Comparison 2: Targeted vs standard fortification, Outcome 15: Growth velocity, head circumference, mm/d, start of fortification to 12 months' CA
2.16. Analysis
2.16. Analysis
Comparison 2: Targeted vs standard fortification, Outcome 16: Change in BMI, end of intervention
2.17. Analysis
2.17. Analysis
Comparison 2: Targeted vs standard fortification, Outcome 17: Change in BMI, start of fortification to 40 weeks' PMA
2.18. Analysis
2.18. Analysis
Comparison 2: Targeted vs standard fortification, Outcome 18: Change in BMI, start of fortification to 3 months' CA
2.19. Analysis
2.19. Analysis
Comparison 2: Targeted vs standard fortification, Outcome 19: Change in BMI, start of fortification to 6 months' CA
2.20. Analysis
2.20. Analysis
Comparison 2: Targeted vs standard fortification, Outcome 20: Change in BMI, start of fortification to 12 months' CA
2.21. Analysis
2.21. Analysis
Comparison 2: Targeted vs standard fortification, Outcome 21: Length of hospital stay, days
2.22. Analysis
2.22. Analysis
Comparison 2: Targeted vs standard fortification, Outcome 22: Postmenstrual age at discharge, weeks
2.23. Analysis
2.23. Analysis
Comparison 2: Targeted vs standard fortification, Outcome 23: In‐hospital mortality
2.24. Analysis
2.24. Analysis
Comparison 2: Targeted vs standard fortification, Outcome 24: Necrotizing enterocolitis
2.25. Analysis
2.25. Analysis
Comparison 2: Targeted vs standard fortification, Outcome 25: Culture‐proven late‐onset bacterial sepsis
2.26. Analysis
2.26. Analysis
Comparison 2: Targeted vs standard fortification, Outcome 26: Retinopathy of prematurity, any
2.27. Analysis
2.27. Analysis
Comparison 2: Targeted vs standard fortification, Outcome 27: Osteopenia
2.28. Analysis
2.28. Analysis
Comparison 2: Targeted vs standard fortification, Outcome 28: Bronchopulmonary dysplasia
2.29. Analysis
2.29. Analysis
Comparison 2: Targeted vs standard fortification, Outcome 29: BPD subgroup ‐ in‐hospital mortality
2.30. Analysis
2.30. Analysis
Comparison 2: Targeted vs standard fortification, Outcome 30: BPD subgroup ‐ length of hospital stay, days
2.31. Analysis
2.31. Analysis
Comparison 2: Targeted vs standard fortification, Outcome 31: BPD subgroup ‐ postmenstrual age at discharge, weeks
3.1. Analysis
3.1. Analysis
Comparison 3: Adjustable vs standard fortification, Outcome 1: Growth velocity, weight, g/kg/d, end of intervention
3.2. Analysis
3.2. Analysis
Comparison 3: Adjustable vs standard fortification, Outcome 2: Growth velocity, length, mm/d, end of intervention
3.3. Analysis
3.3. Analysis
Comparison 3: Adjustable vs standard fortification, Outcome 3: Growth velocity, head circumference, mm/d, end of intervention
3.4. Analysis
3.4. Analysis
Comparison 3: Adjustable vs standard fortification, Outcome 4: Growth velocity, weight, g/d, end of intervention
3.5. Analysis
3.5. Analysis
Comparison 3: Adjustable vs standard fortification, Outcome 5: Retinopathy of prematurity, any
3.6. Analysis
3.6. Analysis
Comparison 3: Adjustable vs standard fortification, Outcome 6: Osteopenia
3.7. Analysis
3.7. Analysis
Comparison 3: Adjustable vs standard fortification, Outcome 7: Bronchopulmonary dysplasia
4.1. Analysis
4.1. Analysis
Comparison 4: Targeted vs adjustable fortification, Outcome 1: Growth velocity, weight, g/kg/d, end of intervention
4.2. Analysis
4.2. Analysis
Comparison 4: Targeted vs adjustable fortification, Outcome 2: Growth velocity, length, mm/d, end of intervention
4.3. Analysis
4.3. Analysis
Comparison 4: Targeted vs adjustable fortification, Outcome 3: Growth velocity, head circumference, mm/d, end of intervention
4.4. Analysis
4.4. Analysis
Comparison 4: Targeted vs adjustable fortification, Outcome 4: Retinopathy of prematurity, any
4.5. Analysis
4.5. Analysis
Comparison 4: Targeted vs adjustable fortification, Outcome 5: Osteopenia
4.6. Analysis
4.6. Analysis
Comparison 4: Targeted vs adjustable fortification, Outcome 6: Bronchopulmonary dysplasia

Source: PubMed

3
S'abonner